This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the NCI; the Office of Research, Development, and Information, Centers for Medicare & Medicaid Services; Information Management Services, Inc.; and the SEER program tumor registries in the creation of the SEER-Medicare database.
Gradishar WJAnderson BOAbraham J. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2019. Accessed July 31 2019. To view the most recent version visit NCCN.org.
Gradishar WJAnderson BOBalassanian R. NCCN Guidelines Insights: Breast Cancer. Version 1.2016. J Natl Compr Canc Netw 2015;13:1475–1485.
Rocque GBWilliams CPJackson BE. Impact of nonconcordance with NCCN Guidelines on resource utilization, cost, and mortality in de novo metastatic breast cancer. J Natl Compr Canc Netw 2018;16:1084–1091.
Rocque GBWilliams CPKenzik KM. Concordance with NCCN treatment guidelines: relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis. Cancer 2018;124:4231–4240.
Kaisaeng NHarpe SECarroll NV. Out-of-pocket costs and oral cancer medication discontinuation in the elderly. J Manag Care Spec Pharm 2014;20:669–675.
Zafar SYMcNeil RBThomas CM. Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract 2015;11:145–150.
Warren JLKlabunde CNSchrag D. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(Suppl 8):IV-3–18.
Danese MDLindquist KDoan J. Effect of central nervous system metastases on treatment discontinuation and survival in older women receiving trastuzumab for metastatic breast cancer. J Cancer Epidemiol 2012;2012:819210.
Stokes METhompson DMontoya EL. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health 2008;11:213–220.
Frank B. Definitions of “cost’ in Medicare utilization files. Research Data Assistance Center. Available at http://resdac.umn.edu/sites/resdac.umn.edu/files/Definitions%20of%20%27Cost%27%20in%20Medicare%20Utilization%20Files%20(Slides).pdf. Accessed May 21 2019.
Klabunde CNPotosky ALLegler JM. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–1267.
Charlson MEPompei PAles KL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
Deyo RACherkin DCCiol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
Romano PSRoos LLJollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075–1079; discussion 1081–1090.
Conti RMBernstein ACVillaflor VM. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 2013;31:1134–1139.
Urban RRHe HAlfonso-Cristancho R. The cost of initial care for Medicare patients with advanced ovarian cancer. J Natl Compr Canc Netw 2016;14:429–437.
Bullock AJHofstatter EWYushak ML. Understanding patients’ attitudes toward communication about the cost of cancer care. J Oncol Pract 2012;8:e50–58.
Meisenberg BRVarner AEllis E. Patient attitudes regarding the cost of illness in cancer care. Oncologist 2015;20:1199–1204.
Irwin BKimmick GAltomare I. Patient experience and attitudes toward addressing the cost of breast cancer care. Oncologist 2014;19:1135–1140.
Montero AJEscobar MLopes G. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep 2012;14:1–11.
Montero AJAvancha KGlück S. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat 2012;132:747–751.
Garreau JRDelamelena TWalts D. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg 2006;192:496–498.
Vogel CLCobleigh MATripathy D. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001;61(Suppl 2):37–42.
Townsley CASelby RSiu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005;23:3112–3124.
Muss HBBerry DACirrincione CT. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055–2065.
Hughes KSSchnaper LABerry D. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971–977.
Jolly TAWilliams GRBushan S. Adjuvant treatment of older women with invasive breast cancer. Womens Health (Lond) 2016;12:129–146.
Jolly TWilliams GRJones E. Treatment of metastatic breast cancer in women aged 65 years and older. Womens Health (Lond) 2012;8:455–471.
Kelly RJForde PMElnahal SM. Patients and physicians can discuss costs of cancer treatment in the clinic. J Oncol Pract 2015;11:308–312.
Henrikson NBTuzzio LLoggers ET. Patient and oncologist discussions about cancer care costs. Support Care Cancer 2014;22:961–967.
Neumann PJPalmer JANadler E. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood) 2010;29:196–202.
Kelly RJForde PMBagheri A. Measuring the impact of chemotherapy cost discussions between patients and providers at the time of prescribing [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 257.
Chandra AShafrin JDhawan R. Utility of cancer value frameworks for patients, payers, and physicians. JAMA 2016;315:2069–2070.
Schnipper LEDavidson NEWollins DS. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015;33:2563–2577.
Schnipper LEDavidson NEWollins DS. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 2016;34:2925–2934.
Erten MZDavidoff AJZuckerman IH. The effect of supplemental medical and prescription drug coverage on health care spending for Medicare beneficiaries with cancer. Value Health 2014;17:15–21.
Wan YGao XMehta S. Indirect costs associated with metastatic breast cancer. J Med Econ 2013;16:1169–1178.
Arozullah AMCalhoun EAWolf M. The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol 2004;2:271–278.